Mixed Performance for Dx Firms' Stocks in November as 360Dx Index Rises 2 Percent

Dec 03, 2018

|

NEW YORK (360Dx)– Stocks of many diagnostics firms rebounded in November from a difficult prior month as the 360Dx Index rose almost 2 percent month over month.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Mixed Performance for Dx Firms' Stocks in November as 360Dx Index Rises 2 Percent

To read the full story....

Breaking News

Palmetto Expands Coverage for Decipher Biosciences Prostate Cancer Test

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

ASU Team Wins $6M in Government Funding to Develop Rapid Saliva Testing System for Coronavirus

Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

Genetron, CStone Launch Clinical Trial to Develop CDx for Cancer Drug Avapritinib

Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

What's Popular?

BARDA Awards $5.4M to Luminex for Expanded Respiratory Panel With Coronavirus Target

FDA Grants Emergency Use Authorization for Jiangsu Well Biotech Coronavirus Antibody Test

Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test

Clear Labs Nanopore Sequencing Coronavirus Test Gets FDA Emergency Use Authorization

FDA Grants Emergency Use Authorizations for Quadrant Biosciences, KimForest Coronavirus Tests

Sponsorships